KDR and gastric cancer: Recently, clinical trials in patients with gastric cancer (GC) have been conducted using peptide-based vaccines, including vascular endothelial growth factor receptor 2- (VEGFR2-) 169, VEGFR1-1084, and lymphocyte antigen 6 complex locus K (LY6K-177) epitope peptides [30, 31].